MindBio Therapeutics (MBIO) | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Home
Companies
MindBio Therapeutics

BRIEF

published on 04/16/2024 at 12:45, 7 months 5 days ago

MindBio Therapeutics Announces Share Conversion Request by Riverfort Global Opportunities

Financial News Share Conversion MindBio Therapeutics Securities Law Riverfort Global Opportunities
PRESS RELEASE

published on 04/16/2024 at 12:40, 7 months 5 days ago

Lender Requests to Convert Loan to MindBio Shares
MindBio Therapeutics Corp. announces conversion of loan to shares at $0.05 per Share. Shares subject to 4-month hold period. Company focuses on mental health treatments and microdosing LSD clinical trials

Clinical Trials MindBio Therapeutics Corp. Microdosing LSD Loan Conversion Mental Health Treatments
BRIEF

published on 03/20/2024 at 09:55, 8 months 1 day ago

MindBio Therapeutics Advances to Phase 2B Clinical Trial in Major Depressive Disorder with MB22001

Psychedelic Medicine MB22001 Clinical Trial MindBio Therapeutics Depressive Disorder
PRESS RELEASE

published on 03/20/2024 at 09:50, 8 months 1 day ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results

Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF

published on 03/04/2024 at 11:05, 8 months 17 days ago

MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE

published on 03/04/2024 at 11:00, 8 months 17 days ago

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp

Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
PRESS RELEASE

published on 02/26/2024 at 10:30, 8 months 24 days ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks

Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
BRIEF

published on 02/26/2024 at 10:30, 8 months 24 days ago

MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE

published on 02/14/2024 at 10:00, 9 months 7 days ago

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development

MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE

published on 01/30/2024 at 08:10, 9 months 22 days ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions

MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD

Accesswire

Published on 11/21/2024 at 22:05, 41 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 56 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 31 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 36 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 2 hours 46 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 3 hours 45 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 10 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 4 hours 47 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 4 hours 54 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 4 hours 55 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 15 hours 48 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE